Antibodies to Yersinia; enterocolitica serotype 03, 05, 06 and 09 were measured by the micro-agglutination method in 445 healthy subjects and patients with Grave's disease (n=70), Hashimoto's disease (n=45) and thyroid tumor (n=29). In contrast to previous reports, the incidence of antibodies to serotype 03 in each group of patients with thyroid diseases was not significantly different from that in healthy subjects. However, the incidence of antibodies to serotype 05 was significantly higher in patients with Graves' disease (81.4%, P<0.001) and Hashimoto's disease (91.1%, P<0.001) than in healthy subjects (58.9%). Significantly increased incidence of antibodies to serotypes 06 and 09 was observed only in patients with Hashimoto's disease (40.0% and 51.1% vs healthy subjects 24.7% and 29.9%, respectively). Patients with thyroid tumor showed no increase in any serotype of Yersinia enterocolitica. No correlations was found between the titers of anti-Yersinia antibodies and antithyroglobulin or anti-microsomal antibodies. These data indicate an association between thyroid autoimmunity and antibodies to Yersinia enterocolitica. These results are different from those in reports from other countries, seggesting that serotype specificity may be influenced by racial or genetic factors.
are considered to be caused by genetic autoimmune aberration which may be into be a precipitating factor (Amino and Miyai, 1983) and postpartum onset of Graves' disease (Amino et al., 1987 ) and Hashimoto's disease (Amino et al., 1982 ) is frequently observed clinically.
Some environmental factors, such as bacteria and virus, are also involved in triggering autoimmune dsieases (Glynn, 1976) , but the exact relation between infection with microorganism and thyroid autoimmuity is still unknown.
Infection with the gram-negative bacterium Yersinia enterocolitica induces gastrointestinal symptoms and is sometimes complicated by extra-intestinal symptoms, such as arthritis, erythema nodosum, carditis and iritis (Arvaston et al., 1971) . After infection, development of autoantibodies to nuclear antigen, smooth muscle, parietal cells and renal tubular epithelial cells is frequently observed and thus Yersinia infection has been thought to induce general humoral immune stimulation. (Gripenberg et al., 1978) . In this connection, Bech et al. (1974) first reported a high incidence of antibodies to Yersinia enterocolitica, especially serotype O3, in patients with Graves' disease, Plummer's disease and non-toxic goiter in Denmark. Since then, a similar association between Yersinia antibodies and thyroid disease has been reported from Sweden (Lidman et al., 1974 , Lidman et al., 1976 , Finland (Leino et al., 1988) and West Germany (Wenzel et al., 1988) . A crossreaction between antigens of Yersinia enterocolitica and thyroid epithelial cells has been suggested (Lidman et al., 1976) , and an interesting finding in that Yersinia enterocolitica has thyrotropin (TSH) binding sites (Weiss et al., 1983 , Heyma et al., 1986 .
In contrast, no significant association between antibodies to Yersinia and thyroid diseases was observed in the United kingdom (Keddie et al., 1977) , Australia (Reynolds et al., 1978) or Spain (Saez et al., 1979) . Results on the relation of thyroid diseases with antibodies to serotype O9 are also conflicting (Lidman et al., 1976 , Shenkman and Bottone 1976 , Bech et al., 1977 , Leino et al., 1988 .
In Japan there have been no reports, to our knowledge, on Yersinia antibodies in patients with thyroid diseases. Therefore, we measured antibodies to Yersinia enterocolitica, including the new serotype O5, in patients with thyroid diseases in Osaka.
Materials
and Methods
Subjects
We measured antibodies to Yersinia enterocolitica in 445 normal subjects, 70 patients with Graves' disease, 45 with Hashimoto's disease and 29 with thyroid tumors (22 with cancer and 7 with adenoma). The antithyroid microsomal antibodies of normal subjects were measured to exclude cases of subclinical autoimmune thyroiditis (Amino et al., 1986 Anti-thyroid antibodies Anti-thyroglobulin antibody (TGHA) and anti-thyroid microsomal antibody (MCHA) were assayed by the hemagglutination method described previously (Amino et al., 1976 healthy subjects, and patients with thyroid diseases are shown in Table 1 . Unexpectedly, high incidences of antibodies, especially to serotype O5, were observed even in healthy subjects.
In contrast to reports from Scandinavia and the United States, the incidence of antibodies to serotype 03 in patients with thyroid diseases was not different from that in healthy subjects. However, the incidence of anti-serotype O5 antibodies was significantly increased in patients with Graves' disease and Hashimoto's disease, but not in patients with thyroid
tumor.
An increased incidence of antibodies to serotypes O6 and O9 was observed only in patients with Hashimoto's disease (Table 1 ). Figure 1 shows the distribution of titers of anti-O5 antibodies in healthy subjects and patients with Graves' disease and Hashimoto's disease.
There was no relation between the titers of anti-Yersinia antibodies and MCHA or TGHA. Figure 2 shows the relation of the titers of antibodies to serotype O5 and MCHA in patients with Graves' disease.
Titer of Anti-Yersinia Antibody Fig. 1 and the antibodies to O3 in thyroid diseases have been studied. extensively.
The incidence of anti-O3 antibodies in thyroid disease has been reported to be high in Denmark (Bech et al., 1974 , Bech et al., 1977 , the United States (Shenkman and Bottone, 1976) and Finland (Leino et al.,1988) . However, this has'not been found to be so in the United Kingdom (Keddie et al., 1977) , Australia (Reynolds et al., 1978) and Spain (Saez et al., 1979) . Patients with subclinical autoimmune thyroiditis (Yoshida et al., 1978) were not excluded from healthy subjects in any of these studies. In this study we measured antithyroid microsomal antibodies (MCHA) in all subjects and excluded MCHA-positive subjects from the group of healthy controls. However, the incidence of anti-O3 antibody in healthy subjects was found to be 29.4% in Japan, which is higher than that in Europe or the United States, and we found no difference between its incidences in healthy subjects and the groups with thyroid diseases. This finding supports the results from the United Kingdom, Australia and Spain. Results on the incidence of anti-O9 antibody in thyroid diseases are also conflicting: the incidence is reported to be high in the United States (Shenkman and Bottone, 1976) , but normal in Denmark (Bech et al., 1977) Spain (Saez et al., 1979) and Finland (Leino et al., 1988) . We found that the incidence was high only in Hashimoto's disease in Japan. The antibody to serotype O5
has not been examined before. We found that its incidence was high in Graves' disease and Hashimoto's disease.
The relation of anti-Yersinia antibodies to the nature of the thyroid disease is also important. In Denmark (Bech et al., 1977) and the United States (Shenkman and Bottone, 1976) , a significant association was found between these antibodies and not only autoimmune thyroid disease but also non-autoimmune related diseases, such as toxic and nontoxic nodular goiter. A recent report from Finland (Leino et al., 1988) indicated that IgA class antibodies were present mainly in cases of autoimmune thyroid disease, not in those of other thyroid diseases (toxic nodular goiter, nontoxic nodular goiter, thyroid adenoma and thyroid carcinoma).
In this study we found an association only with autoimmune thyroid disease, suggesting that anti-Yersinia antibodies are related to thyroid autoimmunity but not to thyroid neoplasms.
There are several possible explanations for the association of anti-Yersinia antibodies with thyroid diseases. The first is the cross reaction of an antigen(s) of Yersinia enterocolitica with thyroid cells, as suggested by Lidman et al. (1974 Lidman et al. ( , 1976 ). However, the high incidence of antiYersinia antibodies in non-autoimmune thyroid diseases, the absence of a relationship of these antibodies to anti-thyroid antibodies and the serotype differences in different countries do not indicate this. An interesting recent finding was the demonstration of TSH binding sites on Yersinia enterocolitica (Weiss et al., 1983 , Heyma et al., 1986 . The high incidence of antiYersinia antibodies in thyroid diseases other than Graves' disease is also not compatible with this explanation, although the influence of Yersinia infection on the initiation of Graves' disease cannot be completely excluded.
A second possibility is a common genetic susceptibility to both Yersinia infection and thyroid autoimmunity. The different findings on antibodies to serotype O3 in various countries may be explained by differences in race.
A third possibility is general immune stimulation by Yersinia infection (Gripenberg et al., 1978) . This infection may break through the homeostatic immune surveil- 
